Loading...
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
BACKGROUND: Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the treatment of both early and late stage breast cancer. However, clinical...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
BioMed Central
2010
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2861058/ https://ncbi.nlm.nih.gov/pubmed/20346177 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1757-2215-3-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|